A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular ...
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
As drugs like Ozempic and Wegovy keep flying off the shelves, more and more people are taking the drug into their own hands ...
Berberine, green tea extract and taurine are just some of the ingredients advertised as being able to ‘boost’ GLP-1 levels.
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
However, Dr Kath McCullough, NHS England’s national speciality adviser for obesity, warned that weight loss jabs “are not a ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
A study finds that anti-obesity medications may help reduce alcohol consumption, with nearly half of participants in weight ...